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The clinical impact of infections with respiratory viruses belonging to the family 19 
Paramyxoviridae argues for the development of antiviral therapies with broad-20 
spectrum activity. Favipiravir (T-705) has demonstrated potent antiviral activity 21 
against multiple RNA virus families, and is presently in clinical evaluation for the 22 
treatment of influenza. Here, we demonstrate in vitro activity of T-705, against the 23 
paramyxoviruses Human Metapneumovirus (HMPV), Respiratory Syncytial virus, 24 
Human parainfluenza virus, measles virus, Newcastle Disease virus and Avian 25 
Metapneumovirus. In addition, we demonstrate activity against HMPV in hamsters. 26 
T-705 treatment inhibited replication of all paramyxoviruses tested in vitro, with EC90 27 
values of 8 to 40 µM. Treatment of HMPV-challenged hamsters with 200 mg/kg/day 28 
resulted in 100% protection from infection of the lungs. In all treated and challenged 29 
animals, viral RNA remained detectable in the respiratory tract. The observation that 30 
T-705 treatment had a significant effect on infectious viral titers, with limited effect 31 
on viral genome titers, would be in agreement with its proposed viral mutagenesis 32 
mode of action. However, next generation sequencing of viral genomes isolated from 33 
treated and challenged hamsters did not reveal (hyper)-mutation. Polymerase activity 34 
assays revealed a specific effect of T-705 on the activity of the HMPV viral 35 
polymerase. With the reported antiviral activity of T-705 against a broad range of 36 
RNA virus families, this small molecule would be a promising broad range antiviral 37 
drug candidate to limit the viral burden of paramyxoviruses and to be evaluated for 38 






The family Paramyxoviridae contains a number of viruses causing respiratory tract 44 
illnesses in humans, which together account for a high clinical impact (1). Human 45 
Metapneumovirus (HMPV), Respiratory Syncytial Virus (RSV), and Parainfluenza 46 
virus (PIV) infections are responsible for severe acute respiratory illnesses mainly in 47 
young children, but also in immune compromised and elderly individuals, and are - 48 
together with the influenza viruses (family Orthomyxoviridae) - the primary viral 49 
causes of hospitalizations for severe respiratory tract disease (2-5). No licensed 50 
vaccines or effective antiviral treatments are available for these viruses. Measles 51 
virus, yet another paramyxovirus, is responsible for devastating disease for which the 52 
WHO committed to eradication with the aid of effective vaccines. However, due to 53 
suboptimal immunization levels, resurgence in infections are detected and there is no 54 
effective antiviral treatment available for measles virus infected patients (6-8). 55 
Paramyxoviruses are well known for their zoonotic potential; the Avian Pneumovirus 56 
(AMPV) is the proposed avian ancestor of HMPV  and the avian Newcastle Disease 57 
Virus can cause disease – primarily conjunctivitis - in humans (9-11). Multiple novel 58 
paramyxoviruses have been detected in bats, including close relatives of human 59 
viruses (12, 13) and henipahviruses continue to cause infections in humans in 60 
Australia and Asia (14-17). No licensed vaccines or effective antiviral treatments are 61 
available for any of these viruses. The continuous burden of disease associated with 62 
human and zoonotic paramyxoviruses, argues for the development of antiviral 63 
therapies with broad-spectrum activity against all paramyxoviruses.  64 
Favipiravir (T-705; 6-flouro-3-hydroxy-2-pyrazinecarboxamine) is a pyrazine 65 
derivative that has demonstrated potent antiviral activity against multiple RNA 66 
viruses (18, 19). Intracellular host enzymes act upon T-705, converting T-705 to its 67 
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active form T-705-4-ribofuranosyl-5-triphosphate (T-705RTP) (20). T-705RTP 68 
functions as a purine nucleotide analog that selectively inhibits the RNA-dependent 69 
RNA polymerase (RdRp) or causes lethal mutagenesis upon incorporation into the 70 
viral RNA (21-24). T-705 is presently in clinical development as an influenza virus 71 
inhibitor in Japan (New Drug Application filed) and the United States (Phase 3 72 
clinical trial) (18). Antiviral activity has been demonstrated against a broad range of 73 
negative-stranded RNA viruses, such as members of the Picorna-, Arena-, Bunya-, 74 
and Filoviridae (25-30) and positive strand RNA viruses such as Noro- and 75 
Flaviviruses (31, 32). Here we evaluated activity of T-705 against a broad range of 76 
paramyxoviruses in vitro and against HMPV in hamsters. 77 
 78 
Materials and Methods 79 
Cells and viruses. The construction of recombinant rHMPV NL/00/01-GFP and 80 
NL/99/01-GFP and the generation of wildtype HMPV strains NL/00/17 and 81 
NL/94/01, PIV-3 (clinical isolate from 2001) and Avian Pneumovirus type C 82 
(AMPV-C)  virus stocks in Vero-118 cells have been described previously (33-35). 83 
Stocks of measles virus Edmonston strain expressing GFP (MeV-Edm-GFP; a kind 84 
gift of Dr. P. Duprex) were generated in Vero-Slam cells as described before (36). 85 
The recombinant RSV A2 strain that expresses GFP (RSV-GFP) was a kind gift of 86 
Dr. M.E. Peeples and Dr. P.L. Collins (37). RSV-GFP was grown and titrated in HEp-87 
2 cells in DMEM supplemented with 2% fetal calf serum. Influenza virus stocks 88 
(H1N1 A/Netherlands/602/09) were generated in MDCK cells in Dulbecco modified 89 
Eagle medium (DMEM; Lonza, Breda, The Netherlands) as described (38) and virus 90 
stocks of Herpes Simplex Virus (HSV)-F strain (39) were generated in Vero-118 cells 91 
in a similar way as HMPV, without addition of trypsin but with addition of 2% fetal 92 
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calf serum. Virus stocks of Newcastle Disease Virus (NDV) were generated in 93 
embryonated chicken eggs as described (40). For MeV-Edm-GFP, PIV-3, AMPV-C 94 
and HMPV, infected cells and supernatants were harvested and centrifuged 5 minutes 95 
at 300 x g and the cell-free supernatants were subsequently purified on sucrose 96 
gradients (60-30%) and aliquots were stored at –80 °C. The titer of the virus stocks 97 
was determined by end-point titration in Vero-118 (HMPV, AMPV-C, PIV-3, NDV), 98 
HEp-2 (RSV-GFP), MDCK (influenza virus) or Vero-SLAM (MeV-Edm-GFP) cells 99 
and expressed in tissue culture infectious dose 50 (TCID50)/ ml. Virus titrations were 100 
read out either by fluorescence (rHMPV NL/00/01-GFP, rHMPV NL/99/01-GFP, 101 
RSV-GFP, MeV-Edm-GFP), immune-staining (HMPV NL/94/01 and NL/00/17, 102 
AMPV-C, NDV, PIV-3), standard hemagglutination assays (influenza virus), or by 103 
reading cytopathic effects (HSV). 104 
 105 
In vitro testing. T-705 was obtained from Boc Sciences (New York, USA) and 106 
suspended in DMSO. A serial dilution of T-705 was made in infection medium with a 107 
final DMSO concentration in the cell culture supernatant <0.1%. Control samples 108 
were treated with equal amounts of DMSO as used in the treated samples. Activity of 109 
T-705 was tested against 100 TCID50/well of RSV-GFP in HEp-2 cells, MeV-Edm-110 
GFP in Vero-slam cells, influenza virus in MDCK cells, NDV, AMPV-C, PIV-3 and 111 
HSV in Vero-118 cells, and against 300 TCID50/well of the four genotypes of HMPV 112 
in Vero-118 cells. Inoculations were performed in infection media as described under 113 
‘Cells and viruses’ and references herein. At day 5 (HMPV), 4 (RSV-GFP, NDV, 114 
AMPV-C, PIV-3, MeV-Edm-GFP) or 2 (influenza virus and HSV) after inoculation, 115 
100 µl of supernatant was harvested for virus titration and cells were examined under 116 
the microscope. For those viruses not expressing GFP, immunostaining preceded the 117 
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microscopic examination. EC90 values were calculated based on the dose-response 118 
curves as described (41). 119 
 120 
Immunostaining assays. Immunostaining for HMPV NL/17/00 and NL/94/01, 121 
AMPV-C and NDV was conducted as described previously (34) (40). Similarly, 122 
immunostaining for PIV-3 was conducted using the IMAGEN™ 123 
Immunofluorescence Test for PIV, from Oxoid (Thermo Fisher Scientific, 124 
Landsmeer, The Netherlands).  125 
 126 
Cytotoxicity assay. Quadruplicates of 2 x 104 cells per well in 96-well plates 127 
(Corning) were either mock inoculated or inoculated with a 2-fold serial dilution 128 
series of T-705 in infection medium, starting with a concentration of 250 µM. At time 129 
point 72 hours post inoculation, cell viability was determined using the CytoTox 96 130 
Non-Radioactive Cytotoxicity Assay (Promega, Leiden, the Netherlands) as described 131 
(42). 132 
Polymerase assays using mini-genomes. The construction and use of the mini-133 
genome system for polymerase assays for HMPV has been described (33, 43). The 134 
mini-genome system of HMPV NL/1/00 was used to replace the CAT open reading 135 
frame with that of Firefly Luciferase using standard PCR and cloning assays. As 136 
control, a plasmid was used where the Firefly Luciferase expression was driven by the 137 
T7-promoter (in house development). To test for the effect of T-705 on the 138 
polymerase activity, 5 x 105 293-T cells were plated per well of a 6-well plate in 139 
DMEM medium supplemented with 10% Fetal Calf Serum, 100 U ml-1 penicillin, 100 140 
U ml-1 streptomycin, 2 mM L-glutamine (PSG) 1 mM sodium pyruvate (Life 141 
Technologies, Bleiswijk, The Netherlands) and non-essential amino acids. Cells in 142 
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each well were transfected using the CaPO4 precipitation method (44) with 1 µg 143 
minigenome cDNA construct of HMPV NL/1/00, 50 ng pSV40-Renila-Luciferase 144 
(Promega),, 0.8 µg pCITE-N, 0.4 µg pCITE-P, 0.4 µg pCITE M2.1 and 0.4 µg 145 
pCITE-L (polymerase complex proteins of HMPV). Control cells, to quantify T-7 146 
polymerase activity, were established by transfection with 50 ng SV40-Renila-147 
Luciferase, pT7-Firefly-Luciferase and 1.5 µg pAR3126 (expressing a T7 RNA 148 
polymerase (45)). Transfections were done overnight and medium was refreshed the 149 
next morning with subsequent addition of serial dilutions of T-705. At 48 hours after 150 
transfection, luminescence was measured as described (45). 151 
In vivo testing. Serial dilutions of T-705 were prepared fresh daily by mixing the 152 
correct amount of compound in filtered sterilized 0.4% sodium carboxymethyl 153 
cellulose (CMC) in Milli-Q water. Six 6-week-old Syrian golden hamsters per group 154 
were orally treated with 25-50-100-150-200 mg/kg T-705 solution twice a day, during 155 
4 days, starting 24 hours before nasal-inoculation with 1 x 106 TCID50 HMPV strain 156 
NL/00/01. Throat swabs were collected at day 3 and 4 after inoculation and lungs and 157 
nasal turbinates at 4 days after inoculation for virus titration and real time RT-PCR 158 
assays.  159 
Virus titration and real time PCR assays. Collected lungs, nasal turbinates and 160 
throat swabs were processed as described before (46). In brief, tissues were 161 
homogenized by using a Polytron homogenizer (Kinematica AG) in infection medium 162 
and supernatants were used for virus titration in Vero-118 cells. Titres were calculated 163 
(g tissue)−1, with a detection limit of 101.6 and 101.2 TCID50 (g tissue)−1 for nasal 164 
turbinates and lungs, respectively. Viral RNA was isolated using the MagnaPure LC 165 
system with the MagnaPure LC Total nucleic acid isolation kit (Roche Diagnostics, 166 
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Almere, The Netherlands), with an elution volume of 50 μl. HMPV genome copies 167 
were detected by Taqman real-time qRT-PCR as described (47). 168 
454-sequencing. Viral RNA was extracted from nasal turbinate and lung samples 169 
collected from hamsters, converted to cDNA and amplified by PCR using primers 170 
amplifying 3 overlapping fragments around the polymerase protein gene, covering nt. 171 
6748-8974, nt. 8330-10170 and nt. 10158-12340 and  the complete nucleoprotein 172 
open reading frame (nt. 55-1240), in total constituting 51% of the viral genome. PCR 173 
fragments for each sample were pooled in equal concentrations, and libraries were 174 
created for each sample following the manufacturer’s instructions. Emulsion PCR and 175 
GS Junior 454 sequencing runs were performed according to instructions of the 176 
manufacturer (Roche). Sequence reads were sorted by bar code, trimmed at 30 177 
nucleotides from the 3′ and 5′ ends to remove primer sequences, and the 3′ ends were 178 
further trimmed to improve quality using a Phred score of 20. Reads were aligned to 179 
reference sequence HMPV NL/00/01 (AF371337.2) using CLC Genomics software 180 
4.6.1. The threshold for low frequency variant detection was set at 2%, with quality 181 
values Q ≥ 20.  182 
Animals and ethics regulation. All experiments involving animals were conducted 183 
strictly according to European guidelines (EU directive on animal testing 184 
86/609/EEC) and Dutch legislation (Experiments on Animals Act, 1997). The 185 
experimental protocol was reviewed and approved by an independent animal 186 
experimentation ethical review committee, not affiliated with Erasmus MC (DEC 187 
consult number EMC2949). 188 
Statistics  189 
Statistical analysis was performed with GraphPad 6.0 (GraphPad Software). 190 
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Continuous data between groups were compared using ANOVA. If this test resulted 191 
in P<0.05, then pairwise Mann Whitney tests were performed. 192 
Results 193 
Antiviral activity of T-705 against paramyxoviruses in vitro 194 
The inhibitory effect of T-705 on infection was evaluated for RSV-GFP, PIV-3, 195 
NDV, AMPV-C, MeV-Edm-GFP and prototype strains of the 4 genotypes of HMPV 196 
(rHMPV NL/00/01-GFP (A1), HMPV NL/00/17 (A2), rHMPV NL/99/01-GFP (B1) 197 
and NL/94/01 (B2)). The addition of high concentrations of T-705 (up to 1600 µM) 198 
24 hours prior to inoculation had no or little effect on cell viability, as measured by 199 
cytotoxicity assay. Microscopic examination of the cells revealed that with addition of 200 
increasing T-705 concentrations the number of infected cells decreased for all viruses 201 
tested (Figure 1). For MeV-Edm-GFP, addition of 62.5 µM resulted in the absence of 202 
typical MeV-Edm-GFP induced plaques. For most of the other viruses, a decrease in 203 
infection efficiency of the cells was observed starting at a concentration of 125 µM T-204 
705. Only for RSV-GFP, higher concentrations of the compound were necessary to 205 
decrease infection of HEp-2 cells (Figure 1). 206 
In a next experiment, as a preparation of the in vivo experiments, we set out to mimic 207 
the effect of T-705 in a pre-exposure and post-exposure setting of virus infection in 208 
vitro. Cells were treated at 3 time points: 24 hours prior to-, simultaneous with -, or 24 209 
hours after inoculation. Influenza virus and HSV were taken as sensitive and 210 
insensitive controls, respectively. Furuta et al. reported HSV to be insensitive to T-211 
705 treatment, with EC50 values >625 µM.  In our study, we observed some virus 212 
yield reduction when T-705 was administered 24 hours prior to- and simultaneous 213 
with infection, with EC90 values of 230 and 540 µM, respectively (Table 1). As these 214 
values are significant higher than those obtained for the sensitive influenza virus (P= 215 
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0.0286 and P=0.0286 for treatment prior to-and simultaneous with inoculation; Mann 216 
Whitney P<0.05) and treatment after infection with HSV had no inhibitory effect on 217 
virus release (EC90>1500 µM), our data confirm the insensitivity of HSV to T-705 218 
treatment (Figure 2). Using plaque reduction assays, Furuta et al have reported EC50 219 
values for influenza virus ranging from 0.083 - 2.9 µM (19).  Here, we obtained EC90 220 
values of 1.5 µM and 2.0 µM, for treatment prior to- and simultaneous with infection, 221 
respectively. Taken in account that the employed assays were different, plaque 222 
reduction assays vs. yield reduction and EC50 vs. EC90, these values are in a similar 223 
micromolar range, which confirms the activity of our batch of T-705 against the 224 
influenza virus. However, the influenza virus was significant less sensitive for 225 
treatment after infection, compared to treatment prior to- or simultaneous with 226 
infection (P=0.03 and 0.03, respectively; Mann Whitney P<0.05) (Table 1; Figure 2). 227 
Of all paramyxoviruses tested,  the MeV-Edm-GFP virus  was the most sensitive 228 
virus with EC90 values of 8.6, 9.7 and 13 µM for treatment prior to-, simultaneous 229 
with-, and after inoculation, respectively (Table 1). For treatment prior to- or 230 
simultaneous with infection, these values are significant higher than those for 231 
influenza virus (P=0.03 and P=0.03; Mann Whitney P<0.05), although the EC90 232 
values for MeV-Edm-GFP virus are still in the micromolar range. The MeV-Edm-233 
GFP virus and influenza virus are similarly sensitive to T-705 treatment at 24 hours 234 
after infection, with EC90 values of 57 and 13 µM for influenza virus and the MeV-235 
Edm-GFP virus, respectively (P=0.2; Mann Whitney P<0.05). Together, these data 236 
show that MeV-Edm-GFP is sensitive to treatment with T-705 in a similar 237 
micromolar range as that is effective against influenza virus (Figure 2). 238 
The four genotypes of HMPV were  sensitive to treatment in the same micromolar 239 
rage as the MeV-Edm-GFP virus, with EC90 values ranging from 11-26 µM, 12-34 240 
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µM and 22-43 µM for treatment prior to-, simultaneous with-, and after infection, 241 
respectively (Table 1).  In general, serotype A strains showed to be slightly less 242 
sensitive to T-705 compared to serotype B strains. Although no significant differences 243 
were observed between the four strains for treatment before infection (P= 0.09; 244 
ANOVA P<0.05) or after infection (P= 0.07; ANOVA P<0.05), significant 245 
differences between the four HMPVs were observed for treatment simultaneous with 246 
infection (P= 0.003; ANOVA P<0.05) (Figure 2). This was mainly due to the 247 
significant higher EC90 value of NL/00/17 (34 µM) compared to those of the type B 248 
viruses (15 and 12 µM, for NL/99/01 and NL/94/01, respectively) for this time point 249 
of treatment (P=0.0286 and 0.0286, respectively; Mann Whitney P<0.05). HMPV 250 
strains NL/00/01, NL/99/01 and NL/94/01 were equally sensitive as MeV-Edm-GFP 251 
for treatment prior to inoculation (P=0.34, 0.48 and 0.52, respectively; Mann Whitney 252 
P<0.05). Only NL/00/17 was less sensitive than MeV-Edm-GFP for this treatment 253 
(P=0.03; Mann Whitney P<0.05).   All four HMPVs, as well as MeV-Edm-GFP, were 254 
equally sensitive to treatment after infection as the influenza virus (P=0.14; ANOVA 255 
P<0.05) (Figure 2). These results obtained for four genotypes of HMPV demonstrate 256 
that this virus is  sensitive to treatment in a similar micromolar range as that is 257 
effective against the influenza virus and the MeV-Edm-GFP virus. 258 
T-705 also demonstrated an inhibitory effect on virus release for APMV-C, NDV, 259 
PIV-3 and RSV (Table 1). No significant differences were observed between these 260 
four viruses for the three treatments (P=0.35, 0.08 and 0.37 for prior to-, simultaneous 261 
and after infection, respectively; ANOVAP<0.05). However, the EC90 values of these 262 
four viruses were all significant higher than those for HMPV strain NL/00/01 (P= 263 
0.01, 0.002, 0.02 for prior to-, simultaneous with- and after infection, respectively; 264 
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ANOVAP<0.05), strain NL/99/01 (P= 0.002, 0.0003, 0.02), strain NL/94/01 (P= 265 
0.0015, <0.0001, 0.01), but not than those of HMPV NL/00/17 (P= 0.07, 0.02, 0.08).  266 
All together, these data show that T-705 has an antiviral effect, in the micromolar 267 
range, against all these paramyxoviruses viruses with higher EC90 values for AMPV-268 
C, NDV, PIV-3 and RSV compared to HMPV and MeV-Edm-GFP virus.  269 
 270 
In vivo antiviral activity of T-705 against HMPV 271 
To test the in vivo activity of T-705, an established animal model for HMPV 272 
infections was employed. Syrian golden hamsters were treated with 50-100-150-200-273 
400 mg/kg/d during 4 days, starting 24 hours before nasal-inoculation with 106 274 
TCID50 HMPV strain NL/00/01 (type A1). During this experiment the animals did not 275 
show any signs of illness or weight loss.  276 
Real time RT-PCR assays conducted on throat swabs collected at day 3 and 4 after 277 
inoculation and qRT-PCR assays conducted on nasal turbinate and lung samples 278 
collected at day 4 after inoculation, revealed the presence of viral genomes in these 279 
samples at all given concentrations (Figure 3A and B, top panels). However, the 280 
number of viral genomes in the throat swabs and nasal turbinates decreased 281 
significantly with administration of increasing concentrations of T-705: in the throat 282 
swabs starting at a dose of 100 mg/kg/d at day 3 (P=0.026; Mann Whitney P<0.05), at 283 
a dose of 200 mg/kg/d at day 4 (P=0.01; Mann Whitney P<0.05), and in the nasal 284 
turbinates at a dose of 200 mg/kg/d (P=0.026; Mann Whitney P<0.05). T-705 285 
treatment did not result in a significant decrease in viral genome titers in the lungs (P= 286 
0.2; ANOVA P<0.05), although the titers did decrease with increasing concentrations 287 
of T-705 (Figure 3B, top left panel). Virus titration of the throat swab samples 288 
revealed levels of infectious virus below the limit of detection in 3 (day 3) or 4 (day4) 289 
 13
of the 6 animals treated at a dose of 100 mg/kg/d. In general, infectious virus titers in 290 
the throat swabs decreased significant starting at a dose of 100 mg/kg/d (P=0.0022; 291 
Mann Whitney P<0.05) (Figure 3A, lower panels), and in the nasal turbinates and 292 
lungs at 200 mg/kg/d (P=0.015 and P=0.022, for nasal turbinates and lungs, 293 
respectively; Mann Whitney P<0.05) (Figure 3B, lower levels). Most importantly, at a 294 
dose of 200 mg/kg/d 3 out of 6 animals displayed levels of infectious virus below the 295 
limit of detection in their lungs and at a dose of 400 mg/kg/d none of the animals had 296 
levels of infectious virus above the limit of detection in their lungs (Figure 3B, lower 297 
right panel). 298 
Although replicating virus could not be detected in the lungs of animals treated with 299 
400 mg/kg/d, viral genome titers only declined minimal. These findings of  decreased  300 
infectious virus titers in samples from treated animals with only limited decrease in 301 
viral genome titers, resemble the findings reported for the influenza virus.  In that 302 
study, the infectious virus load in treated samples decreased disproportionately 303 
compared with the RNA copy number. The authors demonstrated that T-705 induced  304 
hypermutation of the viral genome, which explained the decrease in viral titers with 305 
equal titers of  viral genome copies in samples treated with T-705 (24). To investigate 306 
this possibility for the mechanism of action of T-705 against HMPV, samples (nasal 307 
turbinates and lungs) of untreated animals and of high-dose treated animals were 308 
subjected to next generation sequencing (see Table 2). To this end nt. 6748-12340 of 309 
the viral genome (the L open reading frame) for two animals each (H013, H014: 310 
untreated; H044,H045: treated) were subjected to 454-deepsequencing, using 3 311 
overlapping PCR fragments. Overall, this  region was covered by 6892 to 17447 reads 312 
(Figure 4A) and analysis for single nucleotide polymorphisms (SNPs) revealed the 313 
presence of 22 SNPs  in the viral genomes isolated from treated animals that were 314 
 14
also present in the viral genomes retrieved from untreated hamsters (Supplemental 315 
table S1).  This analysis also revealed the presence of approximately 25 reads with T 316 
to C hypermutation, but these were only detected in the sample isolated from the nasal 317 
turbinate of one treated hamster (H043-blue circles in figure 4A around nt.8000). 318 
These hypermutated reads were absent in the lung sample of the same hamster and in 319 
the samples from the other treated  hamster (H044). These hypermutated reads most 320 
likely represent (hypermutated) DIs that occur during HMPV infection, as previously 321 
reported (48), and, based on the absence in the other (treated) samples, are not a result 322 
of T-705 treatment. The T-C hypermutation detected in these reads were included in 323 
calculation of the number of SNPs for  figure 4C, which explains the wide error-bars.  324 
Additional SNPs were detected that were present in untreated samples and absent in 325 
treated samples or the other way around. In the NT samples of untreated animals, 9 326 
(H013) and 10  SNPs (H014) were detected and in these lung samples 4 (H013) and 5 327 
(H014) SNPs were detected that were absent in samples from treated animals, all of 328 
them were present in < 10% of the reads (Supplemental table S1). In the NT of treated 329 
animals 4 SNPs (in both H043 and H044) and in the lungs 16 (H043) and 4 (H044) 330 
SNPs were detected that were absent in the untreated samples. Overall the number of 331 
SNPs detected in this part of the genome did  not differ significantly between the 332 
treated and untreated samples, even when the 25 hypermutated reads detected in the 333 
NT of H043 were included (Figure 4C).  To obtain more evidence and to avoid the 334 
detection of DIs, the nucleoprotein gene of the genomes isolated from the same 335 
animals, and including a third animal per group (H015, H041) was also subjected to 336 
deep sequencing. To this end, one PCR fragment covering the complete ORF was 337 
analyzed, and deep sequencing resulted in  coverage of this region by 338 
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22655 to 49335 reads (Figure 4B). Similar to the results obtained for the polymerase 339 
protein ORF, SNPs detected in the viral genomes isolated from treated animals were 340 
also present in the samples obtained from untreated samples, and were present in only 341 
less than 10% of the reads (Supplemental Table S2). There were no significant 342 
differences between the number of SNPs detected in the nucleoprotein ORF in the 343 
samples obtained for treated and untreated samples (Figure 4C).  Together, next 344 
generation sequencing of approximately 50% of the viral genomes of samples 345 
obtained from treated and untreated animals did not reveal  significant differences in 346 
SNPs detected in treated and untreated samples (Figure 4C), which indicates that T-347 
705 did not induced specific mutations in these parts of the viral genome. 348 
 349 
To investigate whether T-705 had a direct effect on the activity of the polymerase 350 
proteins of HMPV, as described for those of influenza virus and chikungunya virus  351 
(18, 49), the inhibitory effect of T-705 on polymerase complex activity was evaluated 352 
with a mini-genome system. Addition of DMSO alone (data not shown), or increasing 353 
concentrations of T-705 had no inhibitory effect on the expression of the constitutive 354 
expressed Renilla-Luciferase, or on expression of a T7-promoter driven Firefly-355 
luciferase expression plasmid (Figure 5A, left panel). In contrast, addition of 356 
increasing concentrations of T-705 to the mini-genome system of HMPV, expressing 357 
firefly-luciferase, demonstrated an inhibitory effect of T-705 on the HMPV 358 
polymerase activity (Figure 5, black bars).  Addition of 80 µM reduced the activity 359 
with 50%, compared to untreated samples, while addition of 800 µM T-705 360 
significantly reduced the luciferase activity to below 10% (P=0.002; T-test P<0.05). 361 
These data demonstrate that for HMPV the mechanism of action of  T-705 is, at least 362 
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partially, directed against the polymerase activity and not the induction of lethal 363 
mutagenesis of viral genomes.   364 
 365 
Discussion 366 
T-705 has been shown to be effective against important respiratory viruses,  such as 367 
influenza viruses and rhinoviruses. In this study we demonstrated activity of T-705 368 
against important human respiratory viruses of the family Paramyxoviridae: HMPV, 369 
RSV, PIV and the measles virus. The EC90 values detected in vitro were in the low 370 
micromolar range (on average below 10 µg/ml), similar as observed for influenza 371 
virus (EC50 0.013-0.46 ug/ml) (19), bunyaviruses (EC50 5-30 µg/ml), arenaviruses 372 
(0.7-1.2 µg/ml) and picornaviruses (4.8-23 µg/ml) (25). Using plaque reduction 373 
assays, Furuta et al. (19) reported EC50 values of 260 µM for RSV. In our yield 374 
reduction assays, we found EC90 values of 36 to 70 µM for the different treatment 375 
regimens. In both studies, lab adapted strains of RSV were used. The activity of T-376 
705 against RSV might be higher against wild type strains, which would be 377 
worthwhile to investigate. 378 
In addition, differences between observed values may be related to the use of different 379 
assays, such as plaque reduction assays vs reduction in virus yields, and presentation 380 
of the data in EC50 or EC90, but in general these values are sufficiently low to be 381 
translated for in vivo use.  382 
Our results also demonstrate activity against the avian paramyxoviruses AMPV-C and 383 
NDV. Although these viruses do not cause substantial disease in humans, 384 
paramyxoviruses are well known for their zoonotic potential. The activity against 385 
these avian viruses reveals that T-705 has activity against a broad range of 386 
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paramyxoviruses and therefore it is possible that this compound would also be active 387 
against henipahviruses. 388 
To translate in vitro activity into in vivo activity we employed the established hamster 389 
model for HMPV infections (50). In this model, T-705 treatment decreased virus 390 
replication in the throat , nasal turbinates and lungs of the inoculated animals starting 391 
at a dose of 200 mg/kg/d and at dose of  400 mg/kg/d none of the animals had 392 
detectable levels of infectious virus in their lungs. Previous vaccination studies for 393 
HMPV have also resulted in protection of the lungs but not the nasal turbinates upon 394 
challenge. The primary goal of treatment of respiratory virus infections is prevention 395 
of serious lower respiratory tract illnesses, and in this in vivo model treatment with T-396 
705 protected against infection of the lungs. The dose of 200-400 mg/kg/d is similar 397 
to doses used in other animal models for other viruses (19). In addition, these doses 398 
are within the range as reported for influenza virus infection, for which the compound 399 
is now approved in Japan and evaluated in clinical trials elsewhere 400 
(www.clinicaltrials.gov). 401 
Our in vitro pre- and post-exposure experiments revealed that T-705 is more effective 402 
when treatment starts 24 h before infection or during infection. Especially for the 403 
influenza virus and HSV, which are both fast replicating viruses, late addition of the 404 
compound was less effective. Although EC90 values were higher at late addition for 405 
the paramyxoviruses, values for all three treatments were roughly in the same range.  406 
As T-705 needs to be metabolized into its active metabolite T-705-4-ribofuranosyl-5-407 
monophosphate (T-705RMP) and then to T-705-4-ribofuranosyl-5-triphosphate T-408 
705RMP, it requires several hours to reach an effective concentration (21, 51). This 409 
could explain why the compound is less effective against fast replicating viruses when 410 
treatment occurs post infection. Comparison of the results obtained for inhibition of 411 
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infection (Figure 2) and for virus yield reduction (Figure 3) demonstrated that T-705 412 
had more effect on virus yield than on virus infection, as lower concentrations of 413 
compound were needed to reduce the virus yield than to inhibit virus infection.  414 
The mechanism of action of T-705 remains a topic of investigations. Both direct 415 
inhibition of the polymerase as well as induction of lethal mutagenesis have been 416 
described (23, 24, 49, 52). In the T-705 treated hamsters, inoculated with HMPV, 417 
viral genomes were detected in all animals even when treated at high doses. This 418 
presence did not always correlate with the presence of infectious virus, suggestive for 419 
an effect of the compound on the formation of infectious virus. This is further 420 
supported by our data showing that treatment had more effect on virus yields than on 421 
viral infection (Figure 3 vs. Figure 2). Deep sequencing of  approximately half of the 422 
viral genome of samples obtained from untreated and treated animals, did not reveal 423 
any T-705 induced mutations in these parts of the viral genome. As no materials were 424 
left to sequence other parts of the genome, we cannot rule out the presence of 425 
mutations in other parts of the genome that could explain the mechanism of action of 426 
T-705 against HMPV. However, the mutations detected in the afore mentioned 427 
studies on influenza virus, norovirus and chikungunya virus were induced during 428 
passaging of the virus under pressure of high concentrations of T-705. Whether these 429 
types of mutations are also occurring in in vivo situations remains unsure. In a mouse 430 
model for persistent norovirus infections, where the animals were treated for 8 weeks, 431 
an average of 2.9 fold increase in mutation frequencies were found in virus samples 432 
obtained from T-705-treated animals compared to control animals (52). However, in 433 
this case the virus is under pressure for a prolonged period of time (8 weeks), which 434 
cannot be compared with the 4-day treatment in the HMPV hamster model.  435 
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We did detect T-C hypermutation in genomes obtained from the NT of one treated 436 
animal. These were all detected in approximately 25 (hypermutated) reads. These type 437 
or reads with T-C hypermutation have been detected previously during HMPV 438 
infections in vitro (48) and are therefore most likely not a result of T-705 treatment. 439 
This is, as far as we known, the first time that  HMPV DIs  are detected during in vivo 440 
infection, and is of interest for future  investigations.  441 
The absence of (hyper)mutations in the nucleoprotein gene, the region where the 442 
qRT-PCR primers align, proofs that the increase in CT values in T-705 treated 443 
samples (figure 3) are not due to changed sensitivity of the qRT-PCR assay but due to 444 
activity of T-705.  445 
Using mini-genome assays to investigate the effect of T-705 on the polymerase 446 
activity of HMPV, we showed that adding T-705 to this assay resulted in a significant 447 
decrease in the polymerase activity. Currently, there are two hypotheses for the 448 
mechanism of action of T-705: a) the induction of lethal mutagenesis and/or (b) chain 449 
termination by the incorporation of favipiravir-RMP into the nascent RNA strand 450 
(23). Our data indicate that T-705 does not induce lethal mutagenesis on HMPV 451 
genomes, but does have a direct effect on the HMPV polymerase. This is in line with 452 
the activity against the influenza virus polymerase RNA-dependent RNA polymerase 453 
as reported by Kiso et al.  (53) and  with data reported for the chikungunya virus, 454 
where a single mutation in the polymerase protein was sufficient to make the virus 455 
resistant to treatment (49). Although it is  possible that T-705 interferes with viral 456 
morphogenesis at a late stage of the infectious cycle, T-705 is a nucleotide analog and 457 
its mechanism of action is thought to be related to the selective inhibition of viral  458 
RNA-dependent RNA polymerase of influenza virus and many other RNA viruses 459 
(21, 23). Time-of-addition experiments have demonstrated that T-705 inhibits the 460 
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early to intermediate stage of viral replication of arenaviruses and noroviruses (32, 461 
54). However,  the exact mechanism of action against paramyxoviruses still remains 462 
to be elucidated.  463 
In conclusion, we show that T-705 has antiviral activity against a broad panel of 464 
paramyxoviruses, both human and avian. With the reported antiviral activity of T-705 465 
against a broad range of RNA virus families, this small molecule would be a 466 
promising broad range antiviral drug candidate to limit the viral burden of respiratory 467 
viruses and to be evaluated for treatment of (re-) emerging viruses such as the 468 
henipahviruses.  Importantly, elucidation of the mechanism of action of T-705 against 469 
all these viruses would allow the design of novel compounds that employ similar 470 
mechanisms of action, which could help in the development of antiviral treatment 471 
option for a broad spectrum of respiratory viruses. 472 
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Figure  Legends 677 
 678 
FIGURE 1: In vitro testing for T-705 activity against paramyxoviruses. Cells were 679 
treated with serial dilutions of T-705 starting 24 hours prior to inoculation with the 680 
respective virus. At 5 days post inoculation, GFP expressing viruses (RSV-GFP, 681 
MeV-Edm-GFP, rHMPV strains NL/00/01-GFP and NL/99/01-GFP) were examined 682 
directly under a  microscope, and the other viruses were examined after virus specific 683 
immunofluorescence staining as described in the materials and method section. 684 
 685 
FIGURE 2: Virus yield reduction assays. In vitro activity of T-705 against 686 
paramyxoviruses as well as HSV and influenza virus as controls. Cells were treated 687 
starting 24 hours prior to inoculation (black bars), simultaneous with inoculation 688 
(dark grey bars) or 24 hours after inoculation (light grey bars). At 2-5 days after 689 
inoculation, infectious virus yield in the supernatants were determined and EC90 690 
values calculated. Different batches of T-705 were tested and averages and ranges are 691 
given of two independent experiments, both conducted in duplicate. Statistical 692 
analysis were done with One way Anova and Mann Whitney tests, for which results 693 
are described. *=P<0.05; Anova or Mann-Whitney test. 694 
  695 
FIGURE 3: In vivo activity of T-705 against HMPV. Six 6-week old hamsters per 696 
group were orally treated with 50-100-200-300-400 mg/kg.day T-705, during 4 days, 697 
starting 24 hours prior to nasal-inoculation with 106 TCID50 HMPV strain NL/1/00. 698 
Throat swabs were collected at day 3 and 4, nasal turbinates and lungs at 4 days p.i. 699 
A) Ct-values obtained with real-time RT-PCR assays (top panels) and viral titers 700 
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(bottom panels) for throat swabs collected at day 3 (left panels) and day 4 (right 701 
panels). B) Number of HMPV genomes as determined by qRT-PCR (top panels)  and 702 
viral titers (bottom panels) per gram nasal turbinate (left panels) or lung (right 703 
panels). Circles indicate values of individual animals, and black line the average value 704 
of 6 animals. *=P<0.05; **=P<0.01; Mann-Whitney test. 705 
 706 
FIGURE 4: Detection of mutations in the A) Polymerase protein and B) the  707 
nucleoprotein gene of HMPV by 454-sequencing. Graphic representation of 708 
coverage and viral variant analysis in nasal turbinates (NT) and lung tissue (L) for 709 
hamsters untreated (H013;H014;H15)) or treated with 300 (H041) or 400 mg/kg/day 710 
T-705 (H044,H045). Lines indicate the coverage over the target region (left y-axis). Blue 711 
diamonds, black dots and red triangles indicate variants detected per sample. Position 712 
of the dots on the x-axis indicates the position in the sequence where variation was 713 
found. Position on the right y-axis indicates the amount of variation at that position. C) 714 
the number of SNPs detected in the polymerase protein region, the nucleoprotein 715 
region (NT) and combined for both regions of the viral genomes isolated from nasal 716 
turbinates (NT) and lungs from treated and untreated samples. Black spots indicate 717 
individual SNP numbers per animals, the black (horizontal) line the average for all 718 
animals and standard deviations are indicated. Using Mann-Whitney (P<0.05), no 719 
significant differences in number of SNPs between untreated and treated animals was 720 
found.   721 
 722 
FIGURE 5: Effect of T-705 on polymerase activity. 293T cells transfected with: A) 723 
T7-Firefly-Luciferase and transient expressed control (SV40-Renilla-Luciferase) or 724 
B) the HMPV mini-genome system expressing Firefly-Luciferase and  the transient 725 
expressed control (SV40-Renilla-Luciferase) were treated with serial dilutions of T-726 
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705 at 18 hours after transfection. Luminescence was read at 48 hours after 727 
transfection as described in Materials and Methods. Black bars: Firefly-Luciferase 728 
activity; Grey bars: Renilla Luciferase activity. C) Percentage of  luminescence 729 
compared to the untreated samples (luminesce of untreated samples are set at 100%). 730 
Graphs represent values obtained in one, representative, experiment conducted in 731 
duplo. *=P<0.05, T-test. 732 
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Table 1:  733 
In vitro activity of T-705 against paramyxoviruses as well as HSV and influenza virus 734 
as controls. Cells were treated starting 24 hours prior to-, simultaneous with -  or 24 735 
hours after inoculation. At 2-5 days after inoculation, infectious virus yield in the 736 
supernatants were determined and EC90 values calculated. Different batches of T-705 737 
were tested and averages and ranges (st.dev) are given of two independent 738 
experiments, both conducted in duplicate. 739 
 740 
  Prior to - Simultaneous 
with- 
After inoculation 












Influenzavirus 1.5 1.3 2 2.2 57 35 
MeV-Edm-GFP 9 2 10 3 13 7 
HMPV A1 NL/00/01 18 11 26 5 27 9 
HMPV A2 NL/00/17 26 6 34 7 43 9 
HMPV B1 Nl/99/01 13 7 15 10 26 11 
HMPV B2 NL/94/01 11 7 12 7 22 13 
RSV-GFP  36 12 46 14 69 33 
PIV-3  36 3 36 9 68 35 
AMPV-C  40 9 50 7 103 35 
NDV  48 15 55 6 76 11 













Table 2 752 
Information on treatment, Ct values obtained in qRT-PCR and virus titration for 753 
















H013 0 18 7,2x103 17 9,39E+07 
H014 0 25 3,4x103 19 4,60E+07 
H015 0 21 3,4x103 19 2,60E+07 
H041 300 25 0 20 2,09E+07 
H044 400 23 0 21 1,87E+07 
H045 400 24 
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